Court opinion on Losec case a blow for originator firms
This article was originally published in Scrip
In an opinion that will come as a disappointment to originator pharmaceutical companies, an advocate general of the Court of Justice of the EU has recommended that AstraZeneca's appeal against the fine imposed on it seven years ago for alleged abuse of a dominant position regarding its anti-ulcer medicine, Losec, should be dismissed.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.